Posted from: Friday, October 30, 2015 - 11:10 AM - Present

Strensiq Approved for Hypophosphatasia

October 23, 2015 – The U.S. Food and Drug Administration granted approval for Strensiq (asfotase alfa) injection for subcutaneous use. Manufactured by Alexion Pharmaceuticals, Strensiq is indicated to be used to treat three types (pernatal-, infantile-, and juvenile- onset) of hypophosphatasia (HPP). HPP is a very rare inherited disorder of metabolism in which people who suffer from it lack an enzyme critical to the formation of bones and teeth. Untreated HPP may cause further complications such as deformed bones, breathing problems, growth delays, muscle weakness, pain, seizures, and death.

Strensiq is the first medication approved to treat HPP by replacement of the missing enzyme. The recommended dose for Strensiq is 2mg/kg, six times a week. Alexion Pharmaceuticals plans to launch Strensiq by late October and will be available through a limited network of specialty pharmacies.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Thursday, September 21, 2017 - 07:52 AM.